The effect of tapering of remifentanil on postoperative pai
Not Applicable
Completed
- Conditions
- Certain infectious and parasitic diseases
- Registration Number
- KCT0000589
- Lead Sponsor
- Kangbuk Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 62
Inclusion Criteria
1. 19-70 years
2. elective surgery, American Society of Anesthesiologist I-II
3. General anesthesia with desflurane-remifentanil
4. Thyroidectomy
Exclusion Criteria
1.Allergy or hypersensitivity with opioids analgesic
2.Alcohol or drug abuse
3.Chronic opioid, analgesic users
4.Chronic pain
5.Pscychiatric disease
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Postoperative pain (100 Numerical rating scale)
- Secondary Outcome Measures
Name Time Method Rescue analgesic(Pain NRS > 30, Ketorolac 30 mg ivs);Postoperative nausea and vomitting;Rescue antiemetic;Other adverse effect ( Shivering, Dizziness,Headache, Drowsiness);Mean arterial pressure;heart rate;entropy
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie remifentanil's analgesic efficacy in postoperative pain management?
How does remifentanil tapering compare to standard opioid protocols in reducing postoperative analgesic requirements?
Are there specific biomarkers that predict optimal response to remifentanil-based balanced anesthesia strategies?
What adverse events are associated with remifentanil infusion protocols and how are they managed clinically?
How does remifentanil's pharmacokinetic profile influence its effectiveness compared to other opioid-sparing anesthetic techniques?